nonvertebral

But it failed to demonstrate a key difference in other endpoints, such as nonvertebral fractures and clinical vertebral fractures.

Lilly Gives Up on Osteoporosis Drug 2009

In terms of fractures in other parts of the body, referred to collectively as nonvertebral fractures (in places like the clavicle or the wrist) the findings are more mixed, with differing findings depending on whether there is a prior history of fractures and other factors.

Doug Bremner: Ladies, Don't Fall Into the Bone Mineral Density Osteoporosis Trap 2008

The drug also reduced hip fractures by 40%, (0.7% vs. 1.2% on placebo) and nonvertebral fractures by 20% (6.5% vs. 8% on placebo).

Amgen's Bone-Strengthening Drug Clears Big Hurdle 2008

In the only study of men to date, bisphosphonates did not prevent painful vertebral fractures or nonvertebral fractures, including fractures of the hip.

Doug Bremner: Ladies, Don't Fall Into the Bone Mineral Density Osteoporosis Trap 2008

Primary end points were vertebral fractures, estrogen receptor (ER) - positive breast cancer, and nonvertebral fractures; secondary end points included major coronary heart disease events and stroke.

Medlogs - Recent stories 2010

Primary end points were vertebral fractures, estrogen receptor (ER) - positive breast cancer, and nonvertebral fractures; secondary end points included major coronary heart disease events and stroke.

Medlogs - Recent stories 2010

Primary end points were vertebral fractures, estrogen receptor (ER) - positive breast cancer, and nonvertebral fractures; secondary end points included major coronary heart disease events and stroke.

Medlogs - Recent stories 2010

Conclusions In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events.

Medlogs - Recent stories 2010

Conclusions In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events.

Medlogs - Recent stories 2010

Conclusions In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events.

Medlogs - Recent stories 2010